Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both reports explicitly requested empirical validations of these now widely used consensus-based definitions.”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. (2006)
In the citing paper
“Not only were the specific operationalisations of the duration criteria by Frank et al. (1991) and Rush et al. (2006) not empirically supported”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Rush et al. 2006
In the citing paper
“This definition of relapse is the one most commonly used in clinical studies.39”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
(1992) · PubMed · Cited by 33,716
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“These reports have relied on a variety of reasonably chosen remission end points at study exit (eg, 17-item Hamilton Rating Scale for Depression p7 or p6 (HRSD17; Hamilton, 1960, 1967) or MontgomeryÄsberg Depression Rating Scale p10 (MADRS; Montgomery and Äsberg, 1979)).”
MethodThe MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Research works printed but not linked: 2
- American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4): 1–45.
- Weissman AN (1979). The dysfunctional attitude scale. A validation study. Diss Abst Int 40: 1389B–1390B.
Cited by
Items 501–600 of 697
Determining severity subtypes of depression with a self-report questionnaire
Zimmerman, M. A., Martinez, J. H., Friedman, M. A., Boerescu, D. A., Attiullah, N., & Toba, C. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.048 · Cited by 5
“Consistent with most studies on the treatment of depression, remission was defined as a score of seven and below on HAMD, and response was defined as a 50% or greater reduction in HAMD scores from baseline to follow-up (Rush et al., 2006).”
MethodLiu, Y., Zhou, X., Qin, B., Giovane, C. D., Zhang, Y., & Xie, P. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-133 · Cited by 6
Henigsberg, N., Savić, A., Radoš, M., Šarac, H., Radoš, M., Ozretić, D., Janović, M. B., Turk, V. E., Šečić, A., Kalember, P., et al. (2018) · Croatian Medical Journal · doi:10.3325/cmj.2018.59.244 · Cited by 6
Artificial Intelligence and Pharmacogenomics
Iyer, R. K., Athreya, A. P., Wang, L., & Weinshilboum, R. M. (2019) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2019.08.003 · Cited by 5
Clarke, G. N., Sheppler, C. R., Firemark, A. J., Rawlings, A. M., Dickerson, J. F., & Leo, M. C. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.105967 · Cited by 5
Moriarty, A. S., Paton, L. W., Snell, K. I. E., Riley, R. D., Buckman, J. E. J., Gilbody, S. M., Chew-Graham, C. A., Ali, S., Pilling, S., Meader, N., et al. (2021) · Diagnostic and Prognostic Research · doi:10.1186/s41512-021-00101-x · Cited by 5
Jang, K., Kim, S., Lee, C., & Chae, J. (2022) · Journal of International Medical Research · doi:10.1177/03000605221109789 · Cited by 9
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Moeller, S., Lücke, C., Heinen, C., Bewernick, B. H., Aydın, M., Lam, A. P., Grömer, T. W., Philipsen, A., & Müller, H. (2019) · Journal of Visualized Experiments · doi:10.3791/58264-v · Cited by 5
An update on pharmacotherapy for recurrent depression in 2022
Belge, J.-B., Sabbe, A. C. F., & Sabbe, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2223962 · Cited by 7
Zieve, G. G., Sarfan, L. D., Dong, L., Tiab, S. S., Tran, M., & Harvey, A. G. (2023) · Behaviour Research and Therapy · doi:10.1016/j.brat.2023.104419 · Cited by 5
Treatment of Depression Versus Treatment of PTSD
Hollon, S. D. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020173 · Cited by 7
Zieve, G. G., Armstrong, C. C., Richardson, I. M., Garcia, S. B., & Harvey, A. G. (2022) · Cognitive Therapy and Research · doi:10.1007/s10608-022-10293-1 · Cited by 6
Söderholm, J. J., Socada, J. L., Rosenström, T. H., Ekelund, J., & Isometsä, E. T. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.030 · Cited by 9
Ten ways to improve the treatment of depression and anxiety in adults.
Dunlop, B. W., Scheinberg, K., & Dunlop, A. L. (2013) · Europe PMC (PubMed Central) · Cited by 8
Neurofeedback and Psychopharmacology
Konopka, L. M., & Zimmerman, E. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396988-0.00003-9 · Cited by 5
CYP1A2 genotype-dependent effects of smoking on mirtazapine serum concentrations
Scherf‐Clavel, M., Weber, H., Weiß, C., Klüpfel, C., Stonawski, S., Hommers, L. G., Unterecker, S., Domschke, K., Menke, A., Kittel‐Schneider, S., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251337387 · Cited by 6
“Treatment response was defined as ⩾ 50% reduction in depressive symptoms from baseline as ascertained by HAMD-21 scores (Rush et al., 2006).”
Jang, Y. J., Kim, M., Lee, S.-J., Lim, S., & Kim, D. K. (2025) · Medicina · doi:10.3390/medicina61010108 · Cited by 9
“Antidepressant treatment response was categorized as a response or remission based on the HAM-D score at 6 weeks [21].”
Poinsignon, V., Colle, R., Asmar, K. E., Mendez‐David, I., David, D. J. P., Tayeb, A. E. K. A., Chappell, K., Gressier, F., Herrero, H. G., Fève, B., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.012 · Cited by 6
Duffy, L., Marston, L., Lewis, G., & Lewis, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280997 · Cited by 4
Oliveira-Maia, A. J., Morrens, J., Rive, B., Godinov, Y., Cabrieto, J., Perualila, N. J., Barbreau, S., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250980 · Cited by 7
Doan, T. T., Hutton, D. W., Wright, D. R., & Prosser, L. A. (2024) · Applied Health Economics and Health Policy · doi:10.1007/s40258-024-00872-6 · Cited by 5
“Recovery was clinically defined as the absence of symptoms for at least 4 months [36].”
Möller, H. ‐. (2014) · Springer eBooks · doi:10.1007/978-3-319-04627-3_2 · Cited by 7
Antunes, P., & Fleck, M. P. D. A. (2009) · Journal of Ect · doi:10.1097/yct.0b013e3181a2f81c · Cited by 4
Bareš, M., Novák, T., Kopeček, M., Stopková, P., & Höschl, C. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2010.492226 · Cited by 4
“The response to treatment was defi ned as a reduction of MADRS score 50% and remission as the MADRS score equal or less than 10 points [30].”
MethodYaidikar, L., Anil Kumar, D., Thakur, S., & Mudhuluru, N. (2017) · International Journal of Pharmacological Research · doi:10.7439/ijpr.v7i1.3790 · Cited by 5
Romera, I., Luis, M. A., Delgado-Cohen, H., David, P., Ramon, D. J., & Gilaberte, I. (2009) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500802578975 · Cited by 4
“Other authors have shown elsewhere that the degree of resistance to treatment affects the likelihood of achieving remission [35], with treatment-resistant patients achieving lower remission rates than non-resistant patients [12].”
BackgroundMangelsdorf, S. N., Cagliarini, D., Lee, Y. Y., Mihalopoulos, C., Liu, V., Valentine, L., Bendall, S., Koval, P., D'Alfonso, S., Davey, C., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088695 · Cited by 3
“39 Measurement of relapse will be carried out every 3 months (ie, at 3, 6, 9, 12, 15 and 18 months).”
Predictors of short-term response and the role of heavy alcohol use in treatment of depression
Luoto, K. E., Lassila, A., Leinonen, E. V. J., & Kampman, O. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05366-8 · Cited by 4
“For example, the type of treatment (therapy, pharmacotherapy, neuromodulation), the amount and duration of treatment, the severity of symptoms at base-line, other psychiatric disorders, the previous course of the illness and individual genetic vulnerability factors [14].”
BackgroundAtagün, M. İ. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70221 · Cited by 5
Remission is insufficient: predictors and mechanistic models of recurrence in late-life depression
Taylor, W. D., Gerlach, A., Szymkowicz, S. M., Gujral, S., & Andreescu, C. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02324-2 · Cited by 4
Reif, A., Anıl, Y. A., Bitter, I., Buyze, J., Frey, R., Fu, D. J., Godinov, Y., Haggström, L., Kambarov, Y., Nielsen, R., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112801 · Cited by 4
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial
Zisook, S., Moutier, C. Y., Rush, A. J., Johnson, G. R., Tal, I., Chen, P., Davis, L. L., Hicks, P. B., WILCOX, J. A., Planeta, B. M., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723003008 · Cited by 5
“While prompt diagnosis and treatment of MDD prevents suicide (Mann et al., 2021), over half of those with MDD who receive antidepressant medications do not achieve remission (Rush et al., 2006).”
Self-citationBø, R., Kraft, B., Skilbrei, A., Jonassen, R., Harmer, C. J., & Landrø, N. I. (2024) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2024.101982 · Cited by 3
HMM for discovering decision-making dynamics using reinforcement learning experiments
Guo, X., Zeng, D., & Wang, Y. (2024) · Biostatistics · doi:10.1093/biostatistics/kxae033 · Cited by 7
Trajectories of Depression in Late Life: A 1-Year Follow-Up Study
Borza, T., Engedal, K., Bergh, S., Benth, J. Š., & Selbæk, G. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000458148 · Cited by 5
Kim, T. T., Xu, C., & DeRubeis, R. J. (2021) · Behavior Therapy · doi:10.1016/j.beth.2021.10.003 · Cited by 3
PRIDMORE, S. A., O'Reilly, J., Naguy, A., Morey, R., Turnier‐Shea, Y., & Rybak, M. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4451 · Cited by 3
Petrozzi, B. P., Lamadé, E. K., Schneiberg, R., Scharnholz, B., Vítků, J., Hill, M., Stárka, L., Gilles, M., & Deuschle, M. (2023) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2023.106366 · Cited by 3
Vittengl, J. R., Jarrett, R. B., Ro, E., & Clark, L. A. (2024) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230016 · Cited by 3
“…decrease that (1) begins following ADM initiation, (2) is meaningfully large (e.g., at least 50% and/or below a clinically relevant threshold [66]), (3) clearly exceeds background variability (e.g., mean symptom decrease is at least 1.5 times the standard deviation of the patient’s series of…”
InfluentialInflammatory depression is associated with selective glomerular hypofiltration
Veibäck, G. S., Malmgren, L., Asp, M., Ventorp, F., Suneson, K., Grudet, C., Westrin, Å., & Lindqvist, D. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.007 · Cited by 3
The antidepressant efficacy of flurbiprofen in mice: Behavioural assessment
Alberfkani, N., & Naser, A. (2024) · Journal of Advances in VetBio Science and Techniques · doi:10.31797/vetbio.1383152 · Cited by 3
Biomarkers for Antidepressant Selection: iSPOT-D Study
Palmer, D. M. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0046-1 · Cited by 4
Electroconvulsive therapy for preventing relapse and recurrence in people with depression
Munkholm, K., Jørgensen, K. J., & Paludan‐Müller, A. S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015164 · Cited by 3
Changer d’antidépresseur : quand, comment, pourquoi ?
Gourion, D., Galinowski, A., Baraille, L., & Picard, H. (2011) · L Encéphale · doi:10.1016/j.encep.2010.06.008 · Cited by 3
Brain Stimulation Therapies for Mood Disorders: The Continued Necessity of Electroconvulsive Therapy
Nahas, Z. H., & Anderson, B. S. (2011) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390311409037 · Cited by 3
EEG and QEEG biomarkers as predictors of antidepressant treatment response
Radziszewska, M., Kaźmierski, J., & Sobów, T. (2015) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2015.0003 · Cited by 3
Combining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · doi:10.3109/9781420084887-5 · Cited by 4
Defining and Differentiating Treatment-Resistant Depression
Treviño, K. (2012) · Cited by 3
Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder
Kamath, J., DeMartinis, N. A., & Handratta, V. D. (2007) · Future Neurology · doi:10.2217/14796708.2.4.361 · Cited by 3
“Treating only to a clinical response leaves patients with residual symptoms and persistent functional disability [13–15].”
BackgroundChappell, K., Colle, R., Asmar, K. E., Gressier, F., Bouligand, J., Trabado, S., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02765-5 · Cited by 2
“Responders were de fi ned by an improved HDRS score of ≥ 50% relative to baseline, remitters by an HDRS score of ≤ 7 after ≥ 4 weeks of ATD treatment, as recommended by the American College of Neuropsychopharmacology (ACNP) Task Force [19].”
Efficacy of iTBS in adolescent depression: effects on anhedonia and exploratory moderation analyses
Qin, Q., Li, J., Guo, Y., & He, K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121398 · Cited by 3
Ye, S. J., Lu, L., Tan, X. W., & Tor, P. C. (2024) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202496 · Cited by 4
Danon, M., Poupon, D., Courtet, P., & Gorwood, P. A. P. M. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1801 · Cited by 2
“However,theremainingsymptomsarenotevenlydistributed,for example,poorconcentration,sleepdisturbancesandlackofenergy/ fatigue,andanxietyweremorefrequentlyobserved[4,24,25].”
Krause, K. R., Lee, A., Shan, D., Cost, K. T., Hawke, L. D., Cheung, A., Cleverley, K., de Oliveira, C., Quinlan-Davidson, M., Moretti, M. E., et al. (2025) · BMJ Mental Health · doi:10.1136/bmjment-2024-301425 · Cited by 6
Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents
Emslie, G. J., Kennard, B. D., Mayes, T. L., Nightingale-Teresi, J., Carmody, T. J., Hughes, C. W., Rush, A. J., Tao, R., & Rintelmann, J. W. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.3.foc348 · Cited by 2
Self-citationShrinking Health Care Disparities in Women: The Depression Dilemma
Alexander, J. L., Keita, G. P., Toney, S. D., & Golinkoff, M. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-a.1 · Cited by 2
Combination Strategies in Treatment-Resistant Depression
Lopez-Munoz, F. J., Álamo, C., & García‐García, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_28 · Cited by 3
Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission
Munkholm, K., Jørgensen, K. J., & Paludan‐Müller, A. S. (2019) · JAMA · doi:10.1001/jama.2019.17691 · Cited by 2
Emerging role of microRNAs as novel targets of antidepressants
Manoharan, A., & Paul, A. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102906 · Cited by 2
role of the gut microbiota in pathogenesis and treatment of depression
Bogusz, K., Baran, N., Maksymowicz, M., BIELAK, A., NOWAK, A., CYWKA, Ł., Szwed, W., Nowak, A., & Machowiec, P. A. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.31.01.006 · Cited by 2
EPISODE DEPRESIF BERAT DENGAN GEJALA PSIKOTIK : SEBUAH LAPORAN KASUS
Antara, D. P. E. J. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Deflesselle, É., Verstuyft, C., Petit, A., Hardy, P., David, D. J. P., Falissard, B., Fève, B., Rigal, L., Becquemont, L., Corruble, E., et al. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0165 · Cited by 3
The Efficacy of Cognitive Behavioural Therapy for Depression
Jarrett, R. B., & Vittengl, J. R. (2015) · Wiley eBooks · doi:10.1002/9781119114482.ch3 · Cited by 3
Baskaran, A. (2016) · QSpace (Queen's University Library) · Cited by 3
Depression: Response and Remission
Østergaard, S. D., Papakostas, G. I., & D, M. F. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-27772-6_7028-1 · Cited by 3
Self-citationTurnier‐Shea, Y., Peterson, G. M., Rybak, M., & PRIDMORE, S. A. (2024) · Brain Sciences · doi:10.3390/brainsci14050415 · Cited by 1
“HAMD6 scores of <4 indicate remission, >7 indicate full relapse, and scores between >4 and <7 indicate partial remission/relapse [12,13].”
BackgroundMethodHabenular volume changes after venlafaxine treatment in patients with major depression
Etienne, J., Boutigny, A., David, D. J. P., Deflesselle, É., Gressier, F., Becquemont, L., Corruble, E., & Colle, R. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13684 · Cited by 2
Tamm, J., Takano, K., Just, L., Ehring, T. W., Rosenkranz, T., & Kopf‐Beck, J. (2025) · Behavior Therapy · doi:10.1016/j.beth.2025.08.002 · Cited by 1
Zhan, Y., Liu, H., & Wang, Y. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.036 · Cited by 5
“Treatment response was defined as ≥ 50 % reduction in MADRS score from baseline to week 12, while remission was defined as a week 12 MADRS score ≤ 10 (Rush et al., 2006b).”
Moderators of treatment response in late-life depression
Steffens, D. C., Diniz, B. S., Jain, N., Kluewer-DAmico, J., Manning, K. J., & Wang, L. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02337-x · Cited by 1
Mood in association with dietary nutrient intakes and sleep length
Rintamäki, R. M. (2007) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 1
Adake, P., Chandrashekar, R., & Rao, S. (2013) · Indo American Journal of Pharmaceutical Research · Cited by 3
Managing Depression for Residents in Nursing Facilities
Mort, J. R., Remund, K. E., & Bradley, B. A. (2012) · The Consultant Pharmacist · doi:10.4140/tcp.n.2012.494 · Cited by 1
Cooper‐Kazaz, R., Rigbi, A., & Lerer, B. (2010) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2010.04.007 · Cited by 1
“Patients who respond to treatment but remain short of remission suffer from residual symptoms and impaired function and are at increased risk for recurrence [2,3].”
BackgroundTreating depression and achieving remission
Narasimhan, M., & Kannaday, M. H. (2010) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2010.10.004 · Cited by 1
Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome
Cardinale, R., Menkes, M. W., Andrews, C. M., Webb, C. A., Jha, M. K., Trombello, J. M., Trivedi, M. H., McInnis, M. G., & Deldin, P. J. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09891-1 · Cited by 1
Self-citationMoriarty, A. S., Robertson, L., Mughal, F., Cook, N., Gilbody, S. M., McMillan, D., Chew-Graham, C. A., Ali, S., Hetrick, S. E., Churchill, R. C., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014832 · Cited by 3
“Rush 2006 Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, et al. Report by the ACNP Task Force on response and remission in major depressive disorder.”
BackgroundCombining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · Medical psychiatry · doi:10.3109/9781420084887.003 · Cited by 2
Mansoor, Z., Stanley, J., Fortune, S. A., Havighurst, S. S., & Bell, E. M. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01282-6 · Cited by 3
“In interpreting results, meaningful improvement has been suggested as at least a 50% reduction in the raw score or at least a 25% reduction for youth with treatment-resistant depression or remission defined as a T-score under 65 [44, 45].”
BackgroundReber, S., Herr, A. S., Unterecker, S., & Scherf‐Clavel, M. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001285 · Cited by 1
Pharmacologic neuromodulation for bloating
Madva, E. N., Varma, S., Small, V., Dekel, M., Salamone, S., Murray, H. B., Kuo, B., & Staller, K. D. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2544306 · Cited by 1
Pharmacological treatment of acute bipolar depression
Sachs, G. S., Sylvia, L. G., & Lund, H. G. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8567-5_9 · Cited by 1
The impact of treating major depression during pregnancy on the postpartum phase
Kent, J. S. (2011) · Loyola eCommons (Loyola University of Chicago) · Cited by 2
Cassidy, T. (2016) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2016.05.00305 · Cited by 1
Remission in depression after treatment: too obvious to clinicians, why so difficult to measure?
Turrina, C., Vita, A., Sacchetti, E., & Civili, S. (2015) · Institutional Research Information System (Università degli Studi di Brescia) · Cited by 1
Seo, M.-S., Jeong, J., Seo, H., Lim, H. K., Kim, T., Park, M., Hong, S., & Han, J. (2014) · 대한정신약물학회지 · Cited by 1
Depresyon Tedavisinde Karşılanmamış İhtiyaçlar: Eştanılı Anksiyete ve Yaklaşım
Dılbaz, N., Darçın, A. E., & Çavuş, S. Y. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2011.11790744 · Cited by 4
Peripheral prognostic biomarkers of response in treatment-resistant depression
Agorastos, A., Gkesoglou, T., Kleidonopoulos, A., & Bozikas, V. P. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.049 · Cited by 1
Evers, A. G., Klein, M. E., Aloysi, A. S., Murrough, J., & Jha, M. K. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0055 · Cited by 1
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · Medical psychiatry · doi:10.3109/9781420084887.002 · Cited by 1
Self-citation(2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1606883 · Cited by 1
Psychopharmacotherapy of Depressive Disorders
Kavakbasi, E., & Baune, B. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_427 · Cited by 1
Metacognitive Therapy for Major Depressive Disorder: Development and Clinical Potential
Dugas, E. (2012) · Graduate Student Journal of Psychology · doi:10.52214/gsjp.v14i.10882 · Cited by 1
Terachinda, P. (2021) · Chulalongkorn Medical Journal · doi:10.58837/chula.cmj.65.1.12 · Cited by 1
“1 Brunnstrom stages, n (%) Arm 1/2/3 0 (0)/3 (60)/2 (40) 1 (25)/1 (25)/0 (0) 0 (0)/1 (20)/3 (60) 4/5/6 0 (0)/0 (0)/0 (0) 1 (25)/0 (0)/1 (25) 1 (20)/0 (0)/0 (0) Hand 1/2/3 1 (20)/3 (60)/1 (20) 2 (50)/ 0 (0)/0 (0) 4 (80)/0 (0)/1 (20) 4/5/6 0 (0)/0 (0)/0 (0) 0 (0)/ 1 (25)/1 (25) 0 (0)/0 (0)/0 (0) Leg 1/2/3 0 (0)/3 (60)/1…”
Traitements antidépresseurs : critères d’évaluation du résultat thérapeutique
Boulenger, J.-P. (2007) · L Encéphale · doi:10.1016/s0013-7006(07)92073-4 · Cited by 1
Connor, M., Wells, A., & Fisher, P. (2015) · Wiley eBooks · doi:10.1002/9781119114482.ch1 · Cited by 1
Iosifescu, D. V., & Nierenberg, A. A. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.01.002 · Cited by 1
Managing Depression in Primary Care
Culpepper, L., & Johnson, P. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_10
Kokkoli, E. (2013) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.16664
Vascular Heart and Brain Disease and Incident Late-Life Depression
Luijendijk, H. J. (2010) · RePub (Erasmus University Rotterdam)
Metadata
- Authors
- Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., Regier, D. A., Rosenbaum, J. F., Ray, O., & Schatzberg, A. F.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Stanford Medicine (US)
- University of Pittsburgh (US)
- Emory University (US)
- University of Arizona (US)
- American Psychiatric Association (US)
- Harvard University (US)
- Vanderbilt University (US)
- Corresponding author
- Rush, A John
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-06-21
- Volume
- 31
- Issue
- 9
- Pages
- 1841-1853
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2039979496
- Cited by
- 707
- References
- 132
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 29 · 2023: 58 · 2022: 30 · 2021: 47 · 2020: 30 · 2019: 47 · 2018: 35 · 2017: 30 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 36 · 2012: 35
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- major depressive disorder, remission, response, recovery, relapse, recurrence, end points, symptom rating scales, DSM-IV-TR diagnostic criteria, clinical trial results, quality of life
- MeSH terms
- Clinical Trials as Topic, Major Depressive Disorder, Humans, Recurrence, Research Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.